Related Experiment Video

Updated: May 29, 2026

Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models
08:48

Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models

Published on: June 30, 2023

Synaptic mitochondrial pathology in Alzheimer's disease

Heng Du1, Lan Guo, Shirley ShiDu Yan

  • 1Higuchi Bioscience Center, University of Kansas, Lawrence, Kansas, USA.

Antioxidants & Redox Signaling
|September 28, 2011
PubMed
Abstract

Insights

Alzheimer's disease (AD) involves early synaptic mitochondrial damage, driven by amyloid-beta (Aβ). Understanding these Aβ-linked mitochondrial issues is key to Alzheimer's research.

Area of Science:

  • Neuroscience
  • Mitochondrial Biology
  • Alzheimer's Disease Research

Background:

  • Synaptic mitochondrial dysfunction is linked to synaptic failure in neurodegenerative diseases like Alzheimer's.
  • Early synaptic mitochondrial malfunctions in AD include amyloid-beta (Aβ) accumulation, oxidative stress, and impaired respiration.
  • Aβ's impact on mitochondrial motility and dynamics worsens synaptic mitochondrial damage.

Purpose of the Study:

  • To investigate the role of synaptic mitochondrial alterations in Alzheimer's disease (AD) pathogenesis.
  • To understand the connection between amyloid-beta (Aβ) and synaptic mitochondrial dysfunction.
  • To explore Aβ-associated synaptic mitochondrial perturbations for insights into synaptic stress in AD.

Main Methods:

  • Analysis of human AD subjects.
  • Studies on AD animal models.
  • Investigation using AD cellular models.

Main Results:

  • Synaptic mitochondria show early deficits in Alzheimer's disease.
  • These deficits occur before widespread AD pathology and affect non-synaptic mitochondria.
  • Synaptic mitochondrial dysfunction is a critical factor in early synaptic pathology in AD.

Conclusions:

  • Synaptic mitochondria are vital for maintaining synaptic functions.
  • Synaptic mitochondria are highly vulnerable to amyloid-beta (Aβ).
  • Targeting synaptic mitochondria offers a promising therapeutic strategy for Alzheimer's disease.

More Related Videos

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model06:07

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model

Published on: June 23, 2023

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils15:04

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
ATP Synthase: Mechanism01:48

ATP Synthase: Mechanism

In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased ATP...